regorafenib

You have access
Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience
CARLO SIGNORELLI, DONATELLO GEMMA, ROBERTA GRANDE, SALVATORE DE MARCO, ROSA SALTARELLI, MARIA GRAZIA MORANDI, GIAN PAOLO SPINELLI, FEDERICA ZORATTO, ISABELLA SPERDUTI, MARIO GIOVANNI CHILELLI, ANNA CERIBELLI and ENZO MARIA RUGGERI

Anticancer Research May 2021, 41 (5) 2553-2561; DOI: https://doi.org/10.21873/anticanres.15033
You have access
Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment
YUSUKE NIISATO, TOSHIKAZU MORIWAKI, SHOTA FUKUOKA, TOSHIKI MASUISHI, ATSUO TAKASHIMA, YOSUKE KUMEKAWA, TAKESHI KAJIWARA, KENTARO YAMAZAKI, TAITO ESAKI, AKITAKA MAKIYAMA, TADAMICHI DENDA, YUKIMASA HATACHI, TAKESHI SUTO, NAOTOSHI SUGIMOTO and YASUHIRO SHIMADA

Anticancer Research April 2021, 41 (4) 2203-2207; DOI: https://doi.org/10.21873/anticanres.14996
You have access
Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib
MARIOS PAPADIMITRIOU and CHRISTOS A. PAPADIMITRIOU

Anticancer Research February 2021, 41 (2) 567-582; DOI: https://doi.org/10.21873/anticanres.14809
You have access
A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer
JOEY MERCIER and IOANNIS A. VOUTSADAKIS

Anticancer Research November 2017, 37 (11) 5925-5934;
You have access
Regorafenib Induces Apoptosis and Inhibits Metastatic Potential of Human Bladder Carcinoma Cells
FEI-TING HSU, CHO-CHIN SUN, CHIA-HSING WU, YEN-JU LEE, CHIH-HUNG CHIANG and WEI-SHU WANG

Anticancer Research September 2017, 37 (9) 4919-4926;
You have access
Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
TOSHINORI SUEDA, DAISUKE SAKAI, TOSHIHIRO KUDO, TAKASHI SUGIURA, HIDEKAZU TAKAHASHI, NAOTSUGU HARAGUCHI, JUNICHI NISHIMURA, TAISHI HATA, TARO HAYASHI, TSUNEKAZU MIZUSHIMA, YUICHIRO DOKI, MASAKI MORI and TAROH SATOH

Anticancer Research August 2016, 36 (8) 4299-4306;
You have access
Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer
SHUJI ARITA, TSUYOSHI SHIRAKAWA, YUZO MATSUSHITA, HOZUMI KUMAGAI SHIMOKAWA, GEN HIRANO, AKITAKA MAKIYAMA, YOSHIHIRO SHIBATA, SHINGO TAMURA, TAITO ESAKI, KENJI MITSUGI, HIROSHI ARIYAMA, HITOSHI KUSABA, KOICHI AKASHI and EISHI BABA

Anticancer Research April 2016, 36 (4) 1959-1966;
You have access
Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats
KAZUO HOTTA, JUN UEYAMA, YASUAKI TATSUMI, IKUTO TSUKIYAMA, YUKA SUGIURA, HIROKO SAITO, KATSUHIKO MATSUURA and TAKAAKI HASEGAWA

Anticancer Research September 2015, 35 (9) 4681-4689;
You have access
Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer
KAZUO SUGITA, KAZUYOSHI KAWAKAMI, TAKASHI YOKOKAWA, YUTARO MAE, WATARU TOYA, AKANE HAGINO, KENICHI SUZUKI, MITSUKUNI SUENAGA, NOBUYUKI MIZUNUMA, TOSHIHARU YAMAGUCHI and TOSHIHIRO HAMA

Anticancer Research July 2015, 35 (7) 4059-4062;
You have access
Reduced Dose of Salvage-line Regorafenib Monotherapy for Metastatic Colorectal Cancer in Japan
GEN HIRANO, AKITAKA MAKIYAMA, CHINATSU MAKIYAMA, TAITO ESAKI, HISANOBU ODA, KEITA UCHINO, MASATO KOMODA, RISA TANAKA, YUZO MATSUSHITA, KENJI MITSUGI, YOSHIHIRO SHIBATA, HOZUMI KUMAGAI, SHUJI ARITA, HIROSHI ARIYAMA, HITOSHI KUSABA, KOICHI AKASHI and EISHI BABA

Anticancer Research January 2015, 35 (1) 371-377;

Main menu

User menu

Search

regorafenib

Pages